| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cancer Survivors | 15 | 2024 | 744 | 2.980 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 15 | 2024 | 2902 | 1.860 |
Why?
|
| Neoplasms, Second Primary | 5 | 2021 | 1387 | 1.470 |
Why?
|
| Telomere | 4 | 2016 | 549 | 1.340 |
Why?
|
| Thyroid Neoplasms | 4 | 2021 | 1884 | 1.190 |
Why?
|
| Telomere Shortening | 2 | 2021 | 56 | 1.180 |
Why?
|
| Leukemia, Myeloid, Acute | 14 | 2024 | 7263 | 1.030 |
Why?
|
| Health Equity | 2 | 2024 | 58 | 1.010 |
Why?
|
| Telomerase | 3 | 2020 | 547 | 0.980 |
Why?
|
| Child | 46 | 2024 | 30517 | 0.960 |
Why?
|
| Telomere-Binding Proteins | 3 | 2020 | 92 | 0.890 |
Why?
|
| Mycoses | 2 | 2021 | 393 | 0.870 |
Why?
|
| Dyskeratosis Congenita | 2 | 2013 | 26 | 0.870 |
Why?
|
| Hodgkin Disease | 4 | 2024 | 1485 | 0.830 |
Why?
|
| Neutropenia | 5 | 2023 | 1007 | 0.790 |
Why?
|
| Telomere Homeostasis | 2 | 2020 | 77 | 0.790 |
Why?
|
| Frailty | 2 | 2021 | 133 | 0.760 |
Why?
|
| Health Status Disparities | 1 | 2024 | 318 | 0.730 |
Why?
|
| Hyperbilirubinemia | 2 | 2022 | 78 | 0.720 |
Why?
|
| Hematologic Neoplasms | 3 | 2024 | 1955 | 0.720 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2022 | 201 | 0.720 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2022 | 205 | 0.700 |
Why?
|
| Neoplasms | 12 | 2024 | 15909 | 0.680 |
Why?
|
| Wearable Electronic Devices | 1 | 2021 | 115 | 0.650 |
Why?
|
| Megakaryocyte Progenitor Cells | 1 | 2018 | 10 | 0.640 |
Why?
|
| Twins, Monozygotic | 1 | 2018 | 136 | 0.610 |
Why?
|
| Long Term Adverse Effects | 1 | 2017 | 23 | 0.590 |
Why?
|
| Down Syndrome | 1 | 2020 | 227 | 0.590 |
Why?
|
| Internet | 2 | 2022 | 690 | 0.580 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2017 | 81 | 0.570 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 625 | 0.570 |
Why?
|
| Adolescent | 28 | 2024 | 32719 | 0.570 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2018 | 204 | 0.550 |
Why?
|
| Siblings | 3 | 2019 | 318 | 0.540 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2024 | 5775 | 0.540 |
Why?
|
| Infertility | 1 | 2017 | 105 | 0.530 |
Why?
|
| Antifungal Agents | 3 | 2024 | 880 | 0.520 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2018 | 460 | 0.500 |
Why?
|
| Radiotherapy | 3 | 2021 | 1857 | 0.490 |
Why?
|
| Genetic Variation | 2 | 2020 | 2165 | 0.490 |
Why?
|
| Cognition Disorders | 1 | 2020 | 762 | 0.490 |
Why?
|
| Gene Rearrangement | 1 | 2018 | 813 | 0.470 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2020 | 4646 | 0.470 |
Why?
|
| Humans | 62 | 2024 | 270631 | 0.460 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2022 | 7017 | 0.460 |
Why?
|
| Minisatellite Repeats | 1 | 2013 | 66 | 0.430 |
Why?
|
| Child, Preschool | 17 | 2024 | 17028 | 0.430 |
Why?
|
| Survivors | 5 | 2024 | 1022 | 0.410 |
Why?
|
| Neurotoxicity Syndromes | 2 | 2024 | 125 | 0.400 |
Why?
|
| Neutrophils | 1 | 2016 | 873 | 0.400 |
Why?
|
| Leukemia, Myeloid | 1 | 2016 | 993 | 0.390 |
Why?
|
| Steroids | 1 | 2013 | 371 | 0.390 |
Why?
|
| Anemia, Aplastic | 1 | 2013 | 232 | 0.380 |
Why?
|
| Fetal Growth Retardation | 1 | 2013 | 232 | 0.370 |
Why?
|
| Health Planning Guidelines | 1 | 2011 | 54 | 0.370 |
Why?
|
| Risk Factors | 14 | 2024 | 17875 | 0.360 |
Why?
|
| Obesity | 3 | 2018 | 2904 | 0.360 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2022 | 2633 | 0.350 |
Why?
|
| Microcephaly | 1 | 2013 | 333 | 0.350 |
Why?
|
| Thrombocytopenia, Neonatal Alloimmune | 1 | 2009 | 2 | 0.340 |
Why?
|
| Hematology | 1 | 2011 | 99 | 0.340 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2022 | 16664 | 0.330 |
Why?
|
| Wolman Disease | 1 | 2009 | 7 | 0.330 |
Why?
|
| Socioeconomic Factors | 2 | 2024 | 1264 | 0.330 |
Why?
|
| Sterol Esterase | 1 | 2009 | 26 | 0.330 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2009 | 90 | 0.330 |
Why?
|
| Isoantibodies | 1 | 2009 | 120 | 0.320 |
Why?
|
| Cellular Senescence | 1 | 2010 | 389 | 0.310 |
Why?
|
| Cardiovascular Diseases | 2 | 2020 | 2211 | 0.310 |
Why?
|
| Incidence | 5 | 2024 | 5821 | 0.300 |
Why?
|
| Proportional Hazards Models | 5 | 2023 | 5100 | 0.300 |
Why?
|
| Female | 31 | 2024 | 148865 | 0.300 |
Why?
|
| Antineoplastic Agents | 4 | 2022 | 14616 | 0.290 |
Why?
|
| Male | 28 | 2024 | 128316 | 0.290 |
Why?
|
| Prognosis | 9 | 2024 | 22473 | 0.280 |
Why?
|
| Young Adult | 11 | 2022 | 22201 | 0.270 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2020 | 3152 | 0.270 |
Why?
|
| Case-Control Studies | 4 | 2021 | 6238 | 0.270 |
Why?
|
| HLA Antigens | 1 | 2009 | 594 | 0.270 |
Why?
|
| Electronics | 2 | 2023 | 62 | 0.260 |
Why?
|
| Methotrexate | 3 | 2024 | 1025 | 0.260 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 1034 | 0.260 |
Why?
|
| Survivorship | 2 | 2024 | 116 | 0.250 |
Why?
|
| Intellectual Disability | 1 | 2013 | 1065 | 0.250 |
Why?
|
| Longitudinal Studies | 2 | 2021 | 2056 | 0.250 |
Why?
|
| Infant | 11 | 2024 | 13982 | 0.240 |
Why?
|
| Candida tropicalis | 1 | 2024 | 24 | 0.240 |
Why?
|
| Societies, Medical | 1 | 2011 | 1320 | 0.240 |
Why?
|
| Lymphocyte Count | 3 | 2022 | 485 | 0.240 |
Why?
|
| Candidiasis, Invasive | 1 | 2024 | 28 | 0.230 |
Why?
|
| Biomarkers, Tumor | 2 | 2019 | 10701 | 0.210 |
Why?
|
| Body Fluids | 1 | 2023 | 121 | 0.200 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2022 | 98 | 0.190 |
Why?
|
| Asparaginase | 1 | 2022 | 195 | 0.190 |
Why?
|
| Retrospective Studies | 13 | 2024 | 39811 | 0.190 |
Why?
|
| Central Venous Catheters | 1 | 2022 | 100 | 0.190 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2024 | 1347 | 0.180 |
Why?
|
| Alphapapillomavirus | 1 | 2022 | 172 | 0.180 |
Why?
|
| Atrial Function, Left | 1 | 2020 | 28 | 0.180 |
Why?
|
| Aftercare | 2 | 2022 | 252 | 0.180 |
Why?
|
| Follow-Up Studies | 5 | 2024 | 15204 | 0.170 |
Why?
|
| Thyroid Diseases | 1 | 2020 | 85 | 0.170 |
Why?
|
| Hypersensitivity | 1 | 2022 | 220 | 0.170 |
Why?
|
| Poverty | 1 | 2023 | 481 | 0.170 |
Why?
|
| Papillomavirus Vaccines | 1 | 2022 | 197 | 0.170 |
Why?
|
| Echocardiography, Doppler | 1 | 2020 | 187 | 0.170 |
Why?
|
| Pancreatitis | 1 | 2022 | 294 | 0.170 |
Why?
|
| Adult | 13 | 2024 | 81946 | 0.170 |
Why?
|
| Infant, Newborn | 6 | 2024 | 8694 | 0.160 |
Why?
|
| Catheterization, Central Venous | 1 | 2022 | 363 | 0.160 |
Why?
|
| Catheter-Related Infections | 1 | 2022 | 274 | 0.160 |
Why?
|
| Introns | 1 | 2020 | 461 | 0.160 |
Why?
|
| Anthracyclines | 1 | 2020 | 339 | 0.160 |
Why?
|
| Aging, Premature | 1 | 2018 | 39 | 0.150 |
Why?
|
| Genome-Wide Association Study | 2 | 2024 | 2348 | 0.150 |
Why?
|
| Bacterial Infections | 1 | 2022 | 508 | 0.150 |
Why?
|
| Amino Acid Substitution | 1 | 2020 | 657 | 0.150 |
Why?
|
| Heart Atria | 1 | 2020 | 354 | 0.150 |
Why?
|
| Stroke Volume | 1 | 2020 | 544 | 0.150 |
Why?
|
| Fatal Outcome | 2 | 2011 | 824 | 0.150 |
Why?
|
| Cohort Studies | 3 | 2021 | 9471 | 0.150 |
Why?
|
| Renal Insufficiency | 1 | 2020 | 310 | 0.140 |
Why?
|
| Venous Thromboembolism | 1 | 2022 | 376 | 0.140 |
Why?
|
| Cerebellar Neoplasms | 1 | 2022 | 478 | 0.140 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2022 | 551 | 0.140 |
Why?
|
| Longevity | 1 | 2018 | 155 | 0.140 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2020 | 742 | 0.140 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2020 | 400 | 0.140 |
Why?
|
| Sleep Wake Disorders | 1 | 2020 | 373 | 0.140 |
Why?
|
| Gene Frequency | 1 | 2020 | 1247 | 0.140 |
Why?
|
| Medulloblastoma | 1 | 2022 | 572 | 0.140 |
Why?
|
| Ventricular Function, Left | 1 | 2020 | 564 | 0.140 |
Why?
|
| Leukocytes | 1 | 2018 | 422 | 0.140 |
Why?
|
| Sepsis | 1 | 2022 | 686 | 0.130 |
Why?
|
| Patient Care Planning | 1 | 2018 | 302 | 0.130 |
Why?
|
| Parent-Child Relations | 1 | 2017 | 266 | 0.130 |
Why?
|
| Acute Kidney Injury | 1 | 2023 | 760 | 0.130 |
Why?
|
| Radiation Pneumonitis | 1 | 2018 | 313 | 0.130 |
Why?
|
| Genetic Association Studies | 1 | 2020 | 1099 | 0.130 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 751 | 0.120 |
Why?
|
| Chronic Disease | 1 | 2020 | 1825 | 0.120 |
Why?
|
| Texas | 3 | 2023 | 6436 | 0.120 |
Why?
|
| Lung Diseases | 1 | 2020 | 755 | 0.120 |
Why?
|
| Induction Chemotherapy | 1 | 2018 | 670 | 0.120 |
Why?
|
| T-Lymphocytes | 2 | 2021 | 3943 | 0.120 |
Why?
|
| Heart Diseases | 1 | 2020 | 723 | 0.120 |
Why?
|
| Echocardiography | 1 | 2020 | 1228 | 0.120 |
Why?
|
| Pilot Projects | 1 | 2021 | 2846 | 0.110 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2014 | 105 | 0.110 |
Why?
|
| Papillomavirus Infections | 1 | 2022 | 999 | 0.110 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 1041 | 0.110 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 1822 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 1416 | 0.110 |
Why?
|
| Alleles | 1 | 2020 | 2590 | 0.110 |
Why?
|
| Guideline Adherence | 1 | 2018 | 632 | 0.110 |
Why?
|
| Surveys and Questionnaires | 2 | 2024 | 5914 | 0.110 |
Why?
|
| Remission Induction | 2 | 2016 | 3652 | 0.100 |
Why?
|
| Radiation Injuries | 1 | 2020 | 1470 | 0.100 |
Why?
|
| Inpatients | 1 | 2017 | 686 | 0.100 |
Why?
|
| Sex Distribution | 1 | 2013 | 495 | 0.100 |
Why?
|
| Epilepsy | 1 | 2020 | 947 | 0.100 |
Why?
|
| Pedigree | 2 | 2014 | 2042 | 0.100 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2013 | 271 | 0.100 |
Why?
|
| Age Distribution | 1 | 2013 | 724 | 0.100 |
Why?
|
| Acute Disease | 1 | 2016 | 2495 | 0.100 |
Why?
|
| Chromosome Aberrations | 1 | 2018 | 2031 | 0.090 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 854 | 0.090 |
Why?
|
| Quality of Life | 2 | 2024 | 4774 | 0.090 |
Why?
|
| Biopsy | 1 | 2018 | 3482 | 0.090 |
Why?
|
| Bone Marrow | 1 | 2018 | 2438 | 0.090 |
Why?
|
| Homozygote | 1 | 2013 | 772 | 0.090 |
Why?
|
| Disease-Free Survival | 3 | 2019 | 10258 | 0.090 |
Why?
|
| Anxiety | 1 | 2017 | 1236 | 0.090 |
Why?
|
| Algorithms | 1 | 2021 | 3900 | 0.090 |
Why?
|
| Philadelphia Chromosome | 1 | 2014 | 852 | 0.090 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 513 | 0.080 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2009 | 37 | 0.080 |
Why?
|
| Germ-Line Mutation | 1 | 2014 | 1101 | 0.080 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2014 | 1143 | 0.080 |
Why?
|
| Translocation, Genetic | 1 | 2014 | 1285 | 0.080 |
Why?
|
| DNA Methylation | 1 | 2018 | 2766 | 0.080 |
Why?
|
| Risk Assessment | 1 | 2021 | 6766 | 0.080 |
Why?
|
| Middle Aged | 5 | 2021 | 90294 | 0.080 |
Why?
|
| Liver Failure | 1 | 2009 | 141 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 2394 | 0.070 |
Why?
|
| Mutation | 2 | 2020 | 15911 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 6253 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2022 | 4960 | 0.070 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 4326 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 4962 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2010 | 16204 | 0.060 |
Why?
|
| Aging | 1 | 2013 | 1550 | 0.060 |
Why?
|
| Neuroblastoma | 1 | 2010 | 705 | 0.060 |
Why?
|
| Selection Bias | 1 | 2024 | 47 | 0.060 |
Why?
|
| Drug Resistance, Fungal | 1 | 2024 | 98 | 0.060 |
Why?
|
| Glioma | 1 | 2014 | 1977 | 0.060 |
Why?
|
| NF-kappa B | 1 | 2010 | 1564 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2010 | 2073 | 0.050 |
Why?
|
| Clinical Trials as Topic | 2 | 2024 | 3844 | 0.050 |
Why?
|
| Personal Satisfaction | 1 | 2023 | 124 | 0.050 |
Why?
|
| Hypokalemia | 1 | 2022 | 61 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2013 | 9290 | 0.050 |
Why?
|
| Risk | 2 | 2018 | 1940 | 0.050 |
Why?
|
| Demography | 1 | 2022 | 432 | 0.050 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2024 | 1072 | 0.050 |
Why?
|
| Drug Therapy | 1 | 2021 | 205 | 0.050 |
Why?
|
| Creatinine | 1 | 2023 | 529 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2022 | 450 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2024 | 1145 | 0.040 |
Why?
|
| Systole | 1 | 2020 | 220 | 0.040 |
Why?
|
| Transplantation Conditioning | 1 | 2009 | 2368 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2021 | 521 | 0.040 |
Why?
|
| Papillomaviridae | 1 | 2022 | 636 | 0.040 |
Why?
|
| Cardiotoxicity | 1 | 2020 | 151 | 0.040 |
Why?
|
| Phenotype | 1 | 2010 | 6504 | 0.040 |
Why?
|
| Biomarkers | 1 | 2010 | 5060 | 0.040 |
Why?
|
| Overweight | 1 | 2022 | 484 | 0.040 |
Why?
|
| Hospitals, Pediatric | 1 | 2023 | 798 | 0.040 |
Why?
|
| Polyethylene Glycols | 1 | 2022 | 654 | 0.040 |
Why?
|
| Observer Variation | 1 | 2020 | 709 | 0.040 |
Why?
|
| Age Factors | 2 | 2020 | 5464 | 0.040 |
Why?
|
| Recurrence | 2 | 2020 | 4875 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2021 | 635 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2023 | 1232 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 4957 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 657 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2020 | 600 | 0.040 |
Why?
|
| Family | 1 | 2021 | 784 | 0.040 |
Why?
|
| Bleomycin | 1 | 2018 | 482 | 0.030 |
Why?
|
| Flow Cytometry | 2 | 2014 | 3044 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2018 | 298 | 0.030 |
Why?
|
| Apoptosis | 1 | 2010 | 7752 | 0.030 |
Why?
|
| Pregnancy | 1 | 2009 | 8117 | 0.030 |
Why?
|
| Parents | 1 | 2023 | 1084 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2022 | 850 | 0.030 |
Why?
|
| SEER Program | 1 | 2019 | 1047 | 0.030 |
Why?
|
| Kidney | 1 | 2023 | 2119 | 0.030 |
Why?
|
| Registries | 1 | 2023 | 2209 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 1442 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2022 | 3144 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2020 | 821 | 0.030 |
Why?
|
| Oligodendroglioma | 1 | 2014 | 105 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 2650 | 0.030 |
Why?
|
| Hospitalization | 1 | 2023 | 2168 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2022 | 1840 | 0.030 |
Why?
|
| Treatment Outcome | 3 | 2020 | 33722 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2018 | 2271 | 0.030 |
Why?
|
| Pediatrics | 1 | 2021 | 1185 | 0.020 |
Why?
|
| Prevalence | 1 | 2019 | 3401 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2018 | 2238 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 4491 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 6191 | 0.020 |
Why?
|
| Gangliosides | 1 | 2010 | 97 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2018 | 4001 | 0.020 |
Why?
|
| Exome | 1 | 2014 | 1248 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2010 | 494 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2014 | 2421 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 4374 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 3344 | 0.020 |
Why?
|
| Lung | 1 | 2018 | 3299 | 0.020 |
Why?
|
| Time Factors | 1 | 2020 | 13017 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2010 | 714 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2010 | 1723 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2010 | 1109 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 3586 | 0.010 |
Why?
|
| Tumor Burden | 1 | 2010 | 2033 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 3603 | 0.010 |
Why?
|
| Aged | 2 | 2023 | 73338 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2010 | 5759 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2017 | 13412 | 0.010 |
Why?
|
| United States | 1 | 2020 | 15834 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 7782 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2010 | 6397 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2010 | 7235 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2010 | 12098 | 0.010 |
Why?
|